Physicochemical descriptors of aromatic character and their use in drug discovery

Journal of Medicinal Chemistry

Volumn 57, Issue 17, 2014, Pages 7206-7215

  Ritchie, Timothy J ^a   Macdonald, Simon J F ^b  

^a TJR Chem   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUND; CARBON; AROMATIC HYDROCARBON; DRUG;

AROMATIC RATIO; AROMATIC RING COUNT; ATOM; CARBOAROMATIC RING COUNT; CHEMICAL PARAMETERS; DRUG DESIGN; HETEROAROMATIC RING COUNT; MEDICINAL CHEMISTRY; PHYSICAL CHEMISTRY; PRODUCT DEVELOPMENT; REVIEW; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; FORECASTING; NOMENCLATURE; PROCEDURES; REPRODUCIBILITY; TRENDS;

CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; FORECASTING; HYDROCARBONS, AROMATIC; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC;

EID: 84907168648     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500515d     Document Type: Review

References (38)

1. Roughley, S. D.; Jordan, A. M. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates J. Med. Chem. 2011, 54, 3451-3479
2. Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in drugs. J. Med. Chem. [Online early access]. DOI: 10.1021/jm4017625. Published Online: Jan 28, 2014; http://pubs.acs.org/doi/abs/10.1021/jm4017625 (accessed May 22, 2014).
3. Salonen, L. M.; Ellermann, M.; Diderich, F. Aromatic rings in chemical and biological recognition: energetics and structures Angew. Chem., Int. Ed. 2011, 50, 4715-4989
4. Adam, F. L.; Gregory, C. F. Palladium-catalyzed coupling reactions of aryl chlorides Angew. Chem., Int. Ed. 2002, 41, 4176-4211
5. Shawn, D. W.; Timothy, E. B.; Joseph, R. M.; Stephen, L. B. A rationally designed universal catalyst for suzuki-miyaura coupling processes13 Angew. Chem., Int. Ed. 2004, 43, 1871-1876
6. Huang, X.; Anderson, K. W.; Zim, D.; Jiang, L.; Klapars, A.; Buchwald, S. L. Expanding Pd-catalyzed bond-forming processes: the first amidation of aryl sulfonates, aqueous amination, and complementarity with Cu-catalyzed reactions J. Am. Chem. Soc. 2003, 125, 6653-6655
7. Yin, J.; Zhao, M. M.; Huffman, M. A.; McNamara, J. M. Pd-catalyzed N-arylation of heteroarylamines Org. Lett. 2002, 4, 3481-3484
8. Yan, A.; Gasteiger, J. Prediction of aqueous solubility of organic compounds based on a 3D structure representation J. Chem. Inf. Comput. Sci. 2003, 43, 429-434
9. Huuskonen, J.; Livingstone, D. J.; Manallack, D. T. Prediction of drug solubility from molecular structure using a drug-like training set SAR QSAR Environ. Res. 2008, 19, 191-212
10. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on compound developability-Are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020
11. Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
12. Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity Drug Discovery Today 2010, 15, 648-655
13. Luker, T.; Alcaraz, L.; Chohan, K. K.; Blomberg, N.; Brown, D. S.; Butlin, R. J.; Elebring, T.; Griffin, A. M.; Guile, S.; St-Gallay, S.; Swahn, B.-M.; Swallow, S.; Waring, M. J.; Wenlock, M. C.; Leeson, P. D. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules Bioorg. Med. Chem. Lett. 2011, 21, 5673-5679
14. Ritchie, T. J.; Macdonald, S. J. F.; Young, R. J.; Pickett, S. D. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types Drug Discovery Today 2011, 16, 164-171
15. Young, R. J.; Green, D. V. S.; Luscombe, C. N.; Hill, A. P. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity Drug Discovery Today 2011, 16, 822-830
16. Yang, Y.; Engkvist, O.; Llinas, A.; Chen, H. Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds J. Med. Chem. 2012, 55, 3667-3677
17. Ritchie, T. J.; Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. Increasing small molecule drug developability in sub-optimal chemical space Med. Chem. Commun. 2013, 4, 673-680
18. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties Med. Chem. Commun. 2011, 2, 91-105
19. Yusof, I.; Segall, M. D. Considering the impact drug-like properties have on the chance of success Drug Discovery Today 2013, 18, 659-666
20. Kier, L. B.; Hall, L. H. Molecular Structure Description: The Electrotopological State; Academic Press: New York, 1999.
21. Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. P. Estimation of aqueous solubility of chemical compounds using E-state indices J. Chem. Inf. Comput. Sci. 2001, 41, 1488-1493
22. Delaney, J. S. ESOL: estimating aqueous solubility directly from molecular structure J. Chem. Inf. Comput. Sci. 2004, 44, 1000-1005
23. Lamanna, C.; Bellini, M.; Padova, A.; Westerberg, G.; Maccari, L. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process J. Med. Chem. 2008, 51, 2891-2897
24. Kramer, C.; Heinisch, T.; Fligge, T.; Beck, B.; Clark, T. A consistent dataset of kinetic solubilities for early-phase drug discovery ChemMedChem 2009, 4, 1529-1536
25. DRAGON software Web site: http://www.talete.mi.it/products/dragon-description.htm (accessed May 22, 2014).
26. Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the chemical beauty of drugs Nat. Chem. 2012, 4, 90-98
27. Ritchie, T. J.; Macdonald, S. J. F. How drug-like are "ugly" drugs: Do drug-likeness metrics predict ADME behaviour in humans? Drug Discovery Today 2014, 19, 489-495
28. Kombo, D. C.; Tallapragada, K.; Jain, R.; Chewning, J.; Mazurov, A. A.; Speake, J. D.; Hauser, T. A.; Toler, S. 3D molecular descriptors important for clinical success J. Chem. Inf. Model. 2013, 53, 327-342
29. Stepan, A. F.; Subramanyam, C.; Efremov, I. V.; Dutra, J. K.; O'Sullivan, T. J.; DiRico, K. J.; McDonald, W. S.; Won, A.; Dorff, P. H.; Nolan, C. E.; Becker, S. L.; Pustilnik, L. R.; Riddell, D. R.; Kauffman, G. W.; Kormos, B. L.; Zhang, L.; Lu, Y.; Capetta, S. H.; Green, M. E.; Karki, K.; Sibley, E.; Atchison, K. P.; Hallgren, A. J.; Oborski, C. E.; Robshaw, A. E.; Sneed, B.; O'Donnell, C. J. Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active gamma-secretase inhibitor J. Med. Chem. 2012, 55, 3414-3424
30. Brown, A.; Brown, T. B.; Calabrese, A.; Ellis, D.; Puhalo, N.; Ralph, M.; Watson, L. Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for a biaryl substituent Bioorg. Med. Chem. Lett. 2010, 20, 516-520
31. GVK Bio Web site: http://www.gvkbio.com/Informatics.html (accessed May 22, 2014).
32. Lovering, F. Escape from Flatland 2: complexity and promiscuity Med. Chem. Commun. 2013, 3, 515-519
33. Nakashima, S.; Yamamoto, K.; Arai, Y.; Ikeda, Y. Impact of physicochemical profiling for rational approach on drug discovery Chem. Pharm. Bull. 2013, 61, 1228-1238
34. Chong, I.-G.; Jun, C.-H. Performance of some variable selection methods when multicollinearity is present Chemom. Intell. Lab. Syst. 2005, 78, 103
35. JChem for Excel Web site: http://www.chemaxon.com/products/jchem-for-office/ (accessed May 22, 2014).
36. Kenny, P. W.; Montanari, C. A. Inflation of correlation in the pursuit of drug-likeness J. Comput.-Aided Mol. Des. 2013, 27, 1-13
37. Hosmer, D. W.; Lemeshow, S. Applied Logistic Regression, 2 nd ed.; Wiley: New York, 2000.
38. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. L. Adv. Drug Delivery Rev. 1997, 23, 3-25